Biogen is scheduled to present its latest data, which shows the company’s ability to meet the diverse needs of multiple sclerosis (MS) patients, at the 2016 American Academy of Neurology's (ANN) annual meeting in Vancouver, Canada.
This is the 68th annual meeting. The company plans to use this opportunity to emphasize the breadth and diversity of its marketing and research dedicated to the variety of needs that MS patients experience.
The data that the company plans to present shows that there is strong, sustained effectiveness with Tecfidera. These results are supported with real-world evidence as well as clinical data.
“MS is a complex, lifelong disease that affects each person differently,” Ralph Kern, senior vice president of Worldwide Medical, said. “Because people with MS have diverse treatment needs, it is critical that they have a variety of therapeutic options available that not only provide robust efficacy and different mechanisms of action, but also offer the flexibility to transition to another treatment, if needed. With the world’s leading MS portfolio and growing pipeline, Biogen continues to focus on MS care to impact the greatest number of people living with MS globally.”
In addition, the company’s new Zinbryta data shows that there is a positive impact on the patients’ cognitive outcomes as well as the reversibility of the company’s targeted participants.